Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies following some recent CureVac legal wins.

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.

Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the ...

U.S. equities were mixed and little changed at midday as a second inflation report this week came in lower than anticipated.

Each share of CureVac, a clinical-stage biotech company, will be exchanged for about $5.46 in BioNTech American depositary shares. Upon the deal’s closing, ...

The CureVac vaccine is of key importance to Europe, which has preordered 225 million doses. The trial in 10 countries in Latin America and Europe will continue, and a final result is not expected ...

CureVac, whose vaccine comes with easier storage requirements than other mRNA shots, laid out a possible path to salvage its vaccine, emphasizing its utility in people 18 to 60 years old.

CureVac N.V.'s CVGBM vaccine showed positive safety and immunogenicity data in Part A of its phase 1 study for resected glioblastoma, with no dose-limiting toxicities.

German biotech CureVac NV (5CV.DE) said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study's main goal and throwing in doubt the potential delivery ...

CureVac’s product belongs to what many scientists refer to as the second wave of Covid-19 vaccines that could collectively ease the world’s demand. Novavax, a company based in Maryland whose ...

CureVac has announced some "encouraging" data on its COVID-19 vaccine candidate. The German company on Monday reported "positive interim data" on its potential coronavirus vaccine, saying it ...